Abstract
MonarchE demonstrated that adjuvant abemaciclib, oral CDK4 & 6 inhibitor + endocrine therapy (ET) significantly improved invasive disease-free survival in HR+, HER2- high-risk early breast cancer (EBC) compared to ET alone. As prescribing practices for ET vary in younger patients (pts), we present here disease characteristics and ET choice in premenopausal pts (preM) enrolled in monarchE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
